Linked e-resources
Details
Table of Contents
Preface; Contents; 1: Epidemiology and Etiology of Ovarian Cancer; 1.1 Introduction; 1.2 General Epidemiology of Ovarian Cancer; 1.3 Current Status and Changes of Ovarian Cancer Incidence Rate; 1.4 Current Status and Changes of Ovarian Cancer Mortality; 1.5 International Comparison of Ovarian Cancer Incidence Rate and Mortality; 1.6 Risk Factors for Ovarian Cancer; References; 2: Hereditary Ovarian Cancer; 2.1 Introduction; 2.2 Hereditary Breast and Ovarian Cancer (HBOC): BRCA-Related Breast and Ovarian Cancer; 2.2.1 Clinical and Molecular Features of HBOC
2.2.2 Ovarian Cancer Screening for Surveillance2.2.3 Risk-Reducing Salpingo-Oophorectomy (RRSO); 2.2.4 Chemoprevention; 2.3 Genes Other than BRCA1/2 Involved in Hereditary Ovarian Cancer; 2.3.1 Mismatch Repair Genes (Lynch Syndrome); 2.3.2 Homologous Recombination Deficiency (HRD)-Related Genes; 2.4 PARP Inhibitors; References; 3: Morphological and Molecular Pathogenesis of Epithelial Ovarian Tumors; 3.1 Introduction; 3.2 Representative Theories Related to the Morphological Pathogenesis of EOTs; 3.2.1 The Theory of the Secondary Müllerian System
3.2.2 The Theory of Imported Disease3.3 Two-Tiered Classification for Clinical, Morphological, and Molecular Pathogenesis; 3.4 Morphological and Molecular Pathogenesis in Four Representative Malignant EOTs; 3.4.1 Serous Carcinoma; 3.4.1.1 High-Grade Serous Carcinoma; 3.4.1.2 Low-Grade Serous Carcinoma; 3.4.2 Endometrioid Carcinoma; 3.4.3 Clear Cell Carcinoma; 3.4.4 Mucinous Carcinoma; References; 4: Screening and Prevention of Ovarian Cancer; 4.1 Introduction; 4.2 Materials and Methods; 4.2.1 Search Strategy and Selection Criteria; 4.3 Results
4.3.1 The Systematic Literature Review4.3.2 Ovarian Cancer Screening in the General Population; 4.3.2.1 CA125; 4.3.2.2 Transvaginal Sonography; 4.3.2.3 Two-Stage Strategies; 4.3.3 Ovarian Cancer Screening in the High-Risk Population; 4.4 Prevention of Ovarian Cancer; 4.4.1 Risk-Reducing Surgical Options; 4.4.1.1 Risk-Reducing Salpingo-Oophorectomy (RRSO); 4.4.1.2 Risk-Reducing Oophorectomy (RRO); 4.4.1.3 Risk-Reducing Salpingectomy (RRS); 4.4.1.4 Tubal Ligation; 4.4.2 Risk-Reducing Pharmacologic Options; 4.5 Prevention of Breast Cancer; 4.5.1 Risk-Reducing Surgical Options
4.5.2 Risk-Reducing Pharmacologic Options4.6 Ovarian Cancer Screening in the Japanese Population; 4.7 Discussion; References; 5: Pathology of Epithelial Ovarian Tumors; 5.1 Introduction; 5.2 Classification and Nomenclature of Epithelial Ovarian Tumors; 5.3 Origin of Ovarian Epithelial Tumors; 5.4 Serous Tumors; 5.4.1 Benign Serous Tumors; 5.4.2 Serous Borderline Tumor/Atypical Proliferative Serous Tumor; 5.4.2.1 Usual Serous Borderline Tumor/Atypical Proliferative Serous Tumor; 5.4.2.2 Micropapillary Variant Serous Borderline Tumor (Noninvasive Low-Grade Serous Carcinoma)
2.2.2 Ovarian Cancer Screening for Surveillance2.2.3 Risk-Reducing Salpingo-Oophorectomy (RRSO); 2.2.4 Chemoprevention; 2.3 Genes Other than BRCA1/2 Involved in Hereditary Ovarian Cancer; 2.3.1 Mismatch Repair Genes (Lynch Syndrome); 2.3.2 Homologous Recombination Deficiency (HRD)-Related Genes; 2.4 PARP Inhibitors; References; 3: Morphological and Molecular Pathogenesis of Epithelial Ovarian Tumors; 3.1 Introduction; 3.2 Representative Theories Related to the Morphological Pathogenesis of EOTs; 3.2.1 The Theory of the Secondary Müllerian System
3.2.2 The Theory of Imported Disease3.3 Two-Tiered Classification for Clinical, Morphological, and Molecular Pathogenesis; 3.4 Morphological and Molecular Pathogenesis in Four Representative Malignant EOTs; 3.4.1 Serous Carcinoma; 3.4.1.1 High-Grade Serous Carcinoma; 3.4.1.2 Low-Grade Serous Carcinoma; 3.4.2 Endometrioid Carcinoma; 3.4.3 Clear Cell Carcinoma; 3.4.4 Mucinous Carcinoma; References; 4: Screening and Prevention of Ovarian Cancer; 4.1 Introduction; 4.2 Materials and Methods; 4.2.1 Search Strategy and Selection Criteria; 4.3 Results
4.3.1 The Systematic Literature Review4.3.2 Ovarian Cancer Screening in the General Population; 4.3.2.1 CA125; 4.3.2.2 Transvaginal Sonography; 4.3.2.3 Two-Stage Strategies; 4.3.3 Ovarian Cancer Screening in the High-Risk Population; 4.4 Prevention of Ovarian Cancer; 4.4.1 Risk-Reducing Surgical Options; 4.4.1.1 Risk-Reducing Salpingo-Oophorectomy (RRSO); 4.4.1.2 Risk-Reducing Oophorectomy (RRO); 4.4.1.3 Risk-Reducing Salpingectomy (RRS); 4.4.1.4 Tubal Ligation; 4.4.2 Risk-Reducing Pharmacologic Options; 4.5 Prevention of Breast Cancer; 4.5.1 Risk-Reducing Surgical Options
4.5.2 Risk-Reducing Pharmacologic Options4.6 Ovarian Cancer Screening in the Japanese Population; 4.7 Discussion; References; 5: Pathology of Epithelial Ovarian Tumors; 5.1 Introduction; 5.2 Classification and Nomenclature of Epithelial Ovarian Tumors; 5.3 Origin of Ovarian Epithelial Tumors; 5.4 Serous Tumors; 5.4.1 Benign Serous Tumors; 5.4.2 Serous Borderline Tumor/Atypical Proliferative Serous Tumor; 5.4.2.1 Usual Serous Borderline Tumor/Atypical Proliferative Serous Tumor; 5.4.2.2 Micropapillary Variant Serous Borderline Tumor (Noninvasive Low-Grade Serous Carcinoma)